Journal
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume 69, Issue 9, Pages 2310-2318Publisher
OXFORD UNIV PRESS
DOI: 10.1093/jac/dku171
Keywords
tuberculosis; clinical trials; CYP3A; HIV
Funding
- Janssen Infectious Diseases BVBA (Belgium)
- Janssen Infectious Diseases BVBA
Ask authors/readers for more resources
Bedaquiline has recently been approved for the treatment of pulmonary multidrug-resistant tuberculosis (TB) as part of combination therapy in adults. It is metabolized primarily by the cytochrome P450 isoenzyme 3A4 (CYP3A4) to a less-active N-monodesmethyl metabolite. Phase I and Phase II studies in healthy subjects and patients with drug-susceptible or multidrug-resistant TB have assessed the pharmacokinetics and drug-drug interaction profile of bedaquiline. Potential interactions have been assessed between bedaquiline and first-and second-line anti-TB drugs (rifampicin, rifapentine, isoniazid, pyrazinamide, ethambutol, kanamycin, ofloxacin and cycloserine), commonly used antiretroviral agents (lopinavir/ritonavir, nevirapine and efavirenz) and a potent CYP3A inhibitor (ketoconazole). This review summarizes the pharmacokinetic profile of bedaquiline as well as the results of the drug-drug interaction studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available